Viola Lee

ベトナムの企業との新たなパートナーシップのお知らせです。 Hoa Lam Shangri La Healthcare社はベトナムで細胞治療を始めとした最先端治療や国際基準の医療サービスを提供している企業です。 このパートナーシップを通じて、アジアの遺伝子細胞治療分野における更なるプレゼンス向上を目指します。 We are pleased to announce a new partnership with a Vietnamese company. Hoa Lam Shangri La Healthcare is a company that provides state-of-the-art therapies and international standard medical services in Vietnam, including cell therapy. This partnership will help us increase our presence in the field of gene and cell therapy in Asia.

37

1件のコメント

Over 90% of MRs in Japan are anxious about their future. 70% are worried about the future of the MR role itself. While "sales > marketing" is still the traditional success path to becoming a Business Unit Head, the landscape is shifting. A recent market mapping project found that only 32 out of 92 Business Unit Leaders in Tokyo's top pharma companies had over two years of sales management experience, highlighting the challenges of transitioning from sales to marketing. Yet, some of the best leaders I know come from diverse backgrounds such as market access, legal, and medical operations. What do these leaders have in common? -Clear career aspirations -High learning agility -Approachability Is the pharma industry ready to break from traditional molds and develop the next generation of leaders? Russell Potter Chase VanDuzer Eriko Tsukamoto Kotaro Otani / 大谷晃太郎 Mark Kadillak https://lnkd.in/gjvKstaP

44

1件のコメント

Highlights of our recent blog articles: ・PMDA Washington Office ・MHLW listed up 78 drugs in its wanted list ・Japanese new guidance on orphan drug development (https://idec-inc.com/blog/) Eliquent Japan is a Japanese regulatory and commercial consulting firm. We support orphan drug consultation, PMDA, the Japanese health authority, consultation and drug licensing support. (https://idec-inc.com/) #pharma #biotech #businessinsights

3

Accessible medical education empowers healthcare professionals (HCPs) to deliver better care. Preventive medicine knowledge, in particular, equips HCPs to tackle potential health crises. 🩺 🇻🇳 That’s why we’re kicking off 2025 with a new partnership with the Ho Chi Minh City Center for Disease Control (HCDC) to launch an educational channel on the Docquity platform. This multi-year initiative will connect over 3,000 HCPs across Vietnam with the latest advancements in disease prevention. Together, we’re building a stronger network dedicated to improving patient outcomes. Here’s to a new year of innovation, collaboration, and healthier futures for all. 🌟 #NewPartnership #PreventiveMedicine #MedicalEducation #Docquity #Vietnam 

46

1件のコメント

Value based care - "We must all shift our mindset from a disease-based delivery system to one that is focused on health and preventive care." In an interview conducted by PharmaBoardroom with our Co-CEO, Dr. Felix Lee, Felix explained the origin of The GBA Healthcare Group 大灣區醫療集團, its vision, its public private partnership strategy and their partnerships with health insurance companies to drive forward the adoption and development of value based care for the Greater Bay Area. The link to the Pharmaboardroom article is set out below: https://lnkd.in/gN-v5JQv The closing remarks for the interview with Pharmaboardroom is also copied below: ***** Our closing remark is to emphasize the need to address the global health challenges of an aging population. We are at the forefront of scientific advancements and are living longer, but we must consider the implications of longer lifespans on healthcare sustainability. It is crucial for payers and providers to collaborate effectively. We cannot have payers withholding payments or providers merely delivering services without thought to overall value. The World Health Organization and our recent commitment to the World Economic Forum pledge highlight the importance of value-based care. As a matter of fact we are the first company in China to adhere to this goal. We must all shift our mindset from a disease-based healthcare system to one that is focused on health and prevention. We need to focus on keeping people healthy and preventing illnesses rather than only treating diseases once they arise. The big question we face is how healthcare companies can thrive while helping citizens to prevent sickness and prevent the preventables. It is a complex issue that requires collective intelligence and innovative solutions. We always say that it is an impossible triangle to balance the competing interests of payers, providers and patients. However, given the urgency of an aging population that is leading to unsustainable healthcare expenditures for governments globally, we are optimistic that new innovations in business models will emerge. We want to be amongst the pioneers in implementing value-based care in Mainland China, and we are ready and willing to join hands with governments, private providers, insurance companies, pharmaceutical companies and investors to help our people live healthier and longer. ***** The GBA Healthcare Group 大灣區醫療集團 Chow Tai Fook Enterprises (CTFE) Patrick Tsang Dr. Felix Lee Kung Kenny Henry Lim Peter FANG Peter Lau FSA MAAA Judith Tam

37

[Published in April 2024] 📈 Vietnamese B2B pharmaceutical platform Buymed, known locally as Thuocsi, sees a remarkable 2x year-on-year revenue growth, hitting $76.4M in 2022 💸 Despite soaring revenues, Buymed's operating losses tripled to $15.3M due to increased administrative expenses and provisions for past obligations. 🌏 Buymed isn't just stopping at Vietnam; it's broadening its marketplace model to Cambodia and Thailand, empowering small pharmacies across Southeast Asia to access affordable drugs. 🔮 As Buymed navigates growing competition and cash flow concerns, it ventures into B2B2C franchising to enhance local drugstores' operations with advanced tech solutions. 💬 With Buymed's aggressive expansion and innovative strategies, can it redefine pharmaceutical distribution in Southeast Asia? What are the potential challenges and opportunities ahead?

1

Welcome to 2 minutes of Insightful dialogue with a Life Science Expert! - December edition Check out Chad's insights on Korea's Rare Diseases Market: 1) Challenges in the Rare Disease Market 2) Why Korea's Rare Disease Market is Attractive 3) Keys to Success in Korea’s Rare Disease Market We would welcome feedback from fellow experts or the opportunity to meet for coffee and discuss further! Chad (ChangDeok) Ji #pharmaceuticals #raredisease #lincolngroup

18

2件のコメント

🌟 Introducing the First Consulting Casebook from Taiwan by NTU Consulting Club 🌟 After nearly 6 months of intense preparation and collaboration, the NTU Consulting Club is thrilled to announce the release of Taiwan's first-ever consulting casebook 📖🎉 ！ As the project manager, I am incredibly excited and proud to see this initiative grow from a mere idea into a comprehensive, 133-page resource. It features 9 cases across various industries, alongside an overview of the consulting industry and key industry insights. And the best part? It's entirely free to access! 📍Why did we embark on this journey? Here are the 3 driving reasons behind this initiative: 1️⃣ Creating a Taiwan-Centric Casebook: While many casebooks from top MBA consulting clubs are highly regarded, we believed we could develop one with a uniquely Taiwanese perspective — reflecting our local context and unique challenges. 2️⃣ Enhancing Accessibility: We aim to make consulting materials more accessible to students in Taiwan who aspire to enter the consulting field. No barriers, just opportunities. 3️⃣ Pioneering and Inspiring: As the first consulting club in Taiwan to create such a resource, we hope to 「拋磚引玉」 — in alignment with our club's core value to "inspire others, shape the future." This is a call to all future talents to build on the foundation we've set and continue this positive cycle. This project represents the collective effort of the NTU Consulting Club's 11th Board Members, and I feel privileged to have led this incredible team of talented individuals in bringing this vision to life. 🙌 A special thank you to our partners Case Crackers, Kimber Y. Tsai, and Adam Y. Chang for their invaluable support and contributions as reviewers. Your insights have been crucial in making this casebook a reality. 🌟 I'm excited to see how this resource will benefit and inspire our community in Taiwan. Let’s keep pushing boundaries and making a positive impact! https://lnkd.in/evGDGt2a #consulting #NTUConsultingClub #leadership #collaboration #consultingcareers #Taiwan #innovation #casebook #careerdevelopment #freelearning #inspiration Rack Su, Liang-Ying Chen, Po Shuo Shen, Yu-Ting (Edwin) Wu, Yu-Hsin (Sheena) Fan, Jessica Chang, Yu-Syuan(Andrew) Pan, Jenny Kao, Catherine（Yuwen) Liu, Hazel Chen, Ping-Hua(Oscar) Ou

117

3件のコメント

Hello everyone, we've posted a new article regarding an expert's insight on how to minimize the drug lag in Japan 😀 https://lnkd.in/gq-Hbqfi According to the article (Different Development Strategies Affecting Japan’s Drug lag between Japan-Based and Foreign-Based Companies | Therapeutic Innovation & Regulatory Science (springer.com)) recently published by Dr. Uyama (Associate Executive Director at PMDA), understanding regional drug development strategies is key in the competitive realm of pharmaceuticals, particularly for those looking to navigate the Japanese market. A recent study comparing strategies over a decade (2012–2021) reveals stark differences in how Japanese and foreign companies approach drug development and licensing, shedding light on the “drug lag” issue. Key Insights: 1. Development Approaches: Japanese firms predominantly utilize an “only-Japan” strategy for 51.1% of products, focusing on domestic markets. Foreign firms, conversely, often adopt “Multi-Regional Clinical Trials (MRCT)” strategies for 54.9% of their products, indicating a more global outlook.  2. Licensing and Drug Lag: Japanese companies show a preference for original products with minimal drug lag when there’s “no approval in the US and EU” (59.1%). However, the figure for “license-in” products with a drug lag of ≥5 years is 52.5%. This trend is not seen in foreign companies’ products.  3. Global Collaboration: The data suggests a pressing need for Japanese firms to engage in global partnerships, especially with emerging foreign companies, to reduce drug lag by considering earlier licensing and adopting global development strategies.   These findings highlight the importance of strategic planning and partnerships in Japan for international business development professionals in the pharmaceutical sector. Embracing a global approach, including engaging in MRCTs and fostering early-stage collaborations, could be key to minimizing drug lag and maximizing market presence. 

13

[Monthly People Reporter Yoo Ji-yeon] With the number of diabetes patients in Korea exceeding 6 million, according to an in-depth report on diabetes management indicators based on the National Health and Nutrition Survey of the Korea Centers for Disease Control and Prevention, the treatment rate and recognition rate are significantly lower for those in their 30s and 40s. According to the data presented by the Korean Diabetes Association in 2020, about 15.83 million people in the pre-diabetes stage, which is at high risk of developing diabetes, were at the level of fasting blood glucose or glycated hemoglobin. CEO Im of HealthiBuddy Co., Ltd. has established a service that helps people manage frequent diabetes without difficulty and form natural habits in their daily lives. 'HealthiBuddy', a comprehensive service platform that helps form lifelong health habits and prevents diabetes and diabetes complications Based on the participants' blood test results, body composition index, continuous glucose data, their lifestyle analysis, HealthiBuddy's internal medicine and rehabilitation medicine specialists and clinical nutritionists guided and improved their lifestyle habits, followed by analysis and coaching according to the improvement goals. Participants who have a high possibility of developing diabetes were attached with a blood sugar measurement sensor and measured blood sugar for 24 hours in a row. Based on the recorded data, it was well received by providing optimal solutions for each individual with experts in the stages of lifestyle analysis, formation and improvement of lifestyle habits and post-war comparison. The results showed that the health of 19 out of 21 people improved, with average blood sugar decreasing by up to 42 mg/dL, and participants were able to visually check blood sugar changes through the HealthiBuddy app and gradually apply blood sugar healthy diet and physical activities in the lives of individuals with diabetes through continuous conversations with dedicated buddies. He also expressed his feelings that he was able to improve his eating habits in a direction suitable for the individual's situation and find vitality by using appropriate exercise habits. Diabetes can start with mild symptoms and be considered insignificant at first, but it is also a chronic metabolic disease that requires constant management because various complications can occur. CEO Im and others focused on learning blood glucose health by users themselves in the form of lifelong habits that add small habits to the life patterns of people suffering from diabetes. "I thought about how to approach blood sugar management, would be life-long effective. Constant communication and support with experts is also an enormous driving force that continues to achieve the goal. With these customized services, you can understand how you can enjoy the fully healthy life throughout your life." https://lnkd.in/g8ihMS5X

10

📢【Taiwan Biotech Shines at the 2024 US BIO】📢 The North American Biotechnology Exhibition (US BIO), held in San Diego, California, USA, is a premier platform for showcasing the latest biotech innovations and promoting international collaboration! 🎉 Our exhibits included: 🔬 Five major technology platforms 💡 Seven innovative technologies 🏢 Taiwan Pavilion 🗣️ Taiwan Biotech Forum Additionally, the delegation visited several key institutions in Phoenix, including: 🧠 Barrow Neurological Institute 🧬 Translational Genomics Research Institute 🏥 Mayo Clinic These exchanges enabled Taiwan to discuss trends in brain and neurological disease treatment, genomics research, precision medicine, next-generation biopharmaceuticals, digital healthcare, and more with top US biotech institutions, creating endless business opportunities! 🤝 A total of 21 Taiwanese companies and academic institutions actively participated. The Taiwan Pavilion attracted significant international attention, leaving a lasting impression on the global stage. We look forward to more opportunities to promote Taiwan-US biotech exchanges and cooperation, creating a brighter future together! 🚀🌐 #2024USBIO #TaiwanBiotech #PrecisionMedicine #InternationalCooperation #DCB #BiotechInnovation #TaiwanUSExchange

8

The third panel at #CAPRIAnnualForum featured KPMG Taiwan's 蘇嘉瑞 (Jarret Su) and AstraZeneca Taiwan's Vita Chien. From the value of global partnerships like Partnership for Health System Sustainability and Resilience (PHSSR) to innovative approaches in #healthcare, the discussion touched on climate change impacts and #aging populations. Vita Chien emphasized the importance of #innovation and #nurses in healthcare, and Jarret Su highlighted Taiwan's strategic position in augmenting healthcare through technology. Read our latest research as the Asia-Pacific hub PHSSR here: https://bit.ly/4a6DVH2

59

🎥Hong Kong and the Greater Bay Area GBA | Key to Public Procurement and Market Entry Navigating the MedTech landscape just got more strategic! Hong Kong's Medical Device Administrative Control System (MDACS) is not just a regulatory requirement—it's a gateway to new opportunities. Recent Updates You Need to Know: - From June 21, 2023: MDACS-listed devices now receive priority in public procurement. - Starting November 1, 2024: All quotations and tenders in the Department of Health (DH) will require MDACS listing or a submitted application with an assigned number. - By 2025: All devices procured by DH must be MDACS-listed. We've put together an insightful video that dives deep into how the MDACS listing can be your gateway to success in Hong Kong and the GBA. Our expert Jacky Li will guide you through the regulatory updates and market entry strategies. Watch Now: https://lnkd.in/gc6qbTT7 For inquiries or support, reach out to our expert team and stay ahead in the dynamic MedTech landscape. #MDACS #HongKong #GBA #RegulatoryUpdates #MarketEntry #HealthcareInnovation #medicaldevice #registration

6

Amgen is accelerating its expansion in Japan. Sales are expected to expand to 86.7 billion yen in 2023, and further sales growth is expected as shown in the table. Amgen Japan's sales are on an upward curve, from 56.3 billion yen in 2021 to 87.9 billion yen in 2023. The company expects to "achieve double-digit growth over the next three years," and the 100 billion yen (6.7 billion USD) mark is within sight. The driving force will be Teppesa, for the treatment of active thyroid eye disease, which was launched in November this year. Inactive thyroid eye disease is scheduled to be added to the indications. The drug price is high at 979,920 yen (6,653 USD), and the drug price calculation included a usefulness premium I (45%) and a marketability premium I (5%), but the premium coefficient was zero due to low disclosure of the cost of goods. The cost of treatment is estimated at about 22.5 million yen (150 thousand USD) for a course of eight doses (23 vials) for a patient weighing 60 kg. The number of patients in Japan is about 35,000.  Amgen plans to launch 12 new products and add 38 new indications by 2031. New drug development covers cardiovascular disease, cancer, bone disease, inflammation/immune diseases, and neurological diseases. The next-generation BiTE antibody Imdelltra (tarlatamab) for small cell lung cancer is scheduled to be launched next year. Migraine onset suppressant Aimovig (erenumab), osteoporosis drug Evenity (romosozumab), and psoriasis drug Otezla (apremilast) are to add pediatric indications. In obesity and type 2 diabetes, a GIPR antibody-GLP-1 peptide conjugate is in the pipeline for Phase 2.   Moderna plans to start selling a cancer vaccine in 2027 at the earliest. Clinical trials have begun for skin cancer, and the company will develop the Japanese market as the first cancer-related product using mRNA technology. Moderna's cancer vaccine uses genetic testing to examine the complex changes in cancer cell markers, and artificially creates cancer markers tailored to each individual using mRNA. Multiple markers made with mRNA are administered to patients as a vaccine, allowing immune cells to recognize the markers and attack cancer cells scattered throughout the body. Moderna is jointly developing a cancer vaccine to treat melanoma with MSD. The vaccine will be used in combination with Keytruda. Clinical trials are already underway, and this combination showed a longer survival time and a significantly reduced risk of recurrence. In addition to Europe and the US, Japan was also included in the pivotal clinical trials. They believe the drug can be introduced to the market in 2027. Moderna is conducting clinical trials for lung cancer, kidney cancer, and other cancers as well. BioNTech is also developing a cancer vaccine jointly with Genentech and confirmed its safety and extended survival time in pancreatic cancer.  The market size of treatments using mRNA technology is expected to reach about 68 billion dollars by 2030.

16